AccuPulse Secures $10M for Pulse Field Ablation System Trial
AccuPulse Medical Technology has secured over $10 million in a Series A funding round. The company will use these funds to advance its Pulse Field Ablation (PFA) system and develop new products.
The funding round was led by Shenzhen Qianhai Capital, with Shanghai Biomedical Industry Equity Investment Fund and Yuanbio Ventures also contributing. This investment follows a previous clinical study on the PFA system development, which was funded by the U.S. Department of Defense prior to the current funding round.
AccuPulse plans to use the funds to finance a clinical trial of its PFA system and support new product development. The PFA system is a non-thermal, non-chemical method for treating atrial fibrillation, offering a potentially safer and more effective alternative to existing treatments.
AccuPulse Medical Technology has raised over $10 million in a Series A funding round, led by Shenzhen Qianhai Capital. The funds will support a clinical trial of the company's Pulse Field Ablation system and drive new product development. This investment follows previous government funding and underscores the potential of AccuPulse's innovative technology in treating atrial fibrillation.
Read also:
- FDA's Generic Mifepristone Approval Sparks Pro-Life Concerns Over Safety and States' Rights
- Understanding Child Development: Causes and Signs of Delays
- Pope Francis' New Book 'Let Us Dream' Offers Unity and Hope for Post-Covid World
- Stephanie Estremera Gonzalez: From Medical Assistant to Residential Manager at The Point/Arc
